HAIKOU, China, May 17, 2017 /PRNewswire/ -- China Pharma
Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma," the "Company"
or "We"), an NYSE MKT listed corporation with its fully-integrated
specialty pharmaceuticals subsidiary based in China, today announced its wholly-owned
subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd.,
participated in PharmChina and API
(Active Pharmaceutical Ingredient) China.
The 77th PHARMCHINA, and the 78th API China takes place on
May 15 - 18, 2017, National
Exhibition and Convention Center, Shanghai, China. With a long history and great influence in
the APAC
region, this event involves pharmaceutical research and
development, production, sales and marketing; is one of the best
platforms to understand the pulse
and latest trends of this industry. There has been
over 120,000 visitors mainly from pharmaceutical
manufacturers, distributors/agents, and pharmacy chains.
Hainan Helpson Medical & Biotechnology Co., Ltd., is showing
around 20 products for the treatment of anti-infection &
respiratory system diseases, central nervous system diseases,
digestive diseases, and other diseases in this event; and is
communicating with a wide range of existing and potential
distributors and API suppliers.
"To participate in this event is to further improve our
market share, strengthen cooperation with upstream and downstream
companies, in-depth understand frontier information, and explore
global layout," China Pharma's President & CEO, Ms.
Li Zhilin. "We have been actively talking to
international API exhibitors to leverage any win-win cooperation
models in the current pharmaceutical policy
environment in China. We will
continue enhancing our fundamentals in operating level to support
and promote our long-term growth."
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical
company that develops, manufactures and markets a diversified
portfolio of products focused on conditions with a high incidence
and high mortality rates in China,
including cardiovascular, CNS, infectious, and digestive diseases.
The Company's cost-effective, high-margin business model is driven
by market demand and supported by new GMP-certified product lines
covering the major dosage forms. In addition, the Company has a
broad and expanding nationwide distribution network across all
major cities and provinces in China. The Company's wholly-owned subsidiary,
Hainan Helpson Medical & Biotechnology Co., Ltd., is located in
Haikou City, Hainan Province. For more information about
China Pharma Holdings, Inc., please visit
www.chinapharmaholdings.com. The Company routinely posts important
information on its website.
Safe Harbor Statement
Certain statements in this press release constitute
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Any statements set forth above that are not historical facts
are forward-looking statements that involve risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements, which may include, but are not
limited to, such factors as the achievability of financial
guidance, success of new product development, unanticipated changes
in product demand, increased competition, downturns in the Chinese
economy, uncompetitive levels of research and development, and
other information detailed from time to time in the Company's
filings and future filings with the United States Securities and
Exchange Commission. The forward-looking statements made herein
speak only as of the date of this press release and the Company
undertakes no duty to update any forward-looking statement to
conform the statement to actual results or changes in the Company's
expectations except as required by applicable law or
regulation.
Contact:
China Pharma Holdings, Inc.
Ms. Diana Na Huang
Phone: +86-898-6681-1730 (China)
Email: hps@chinapharmaholdings.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/china-pharma-holdings-incs-wholly-owned-subsidiary-participated-in-pharmchinaapi-china-conferences-300459156.html
SOURCE China Pharma Holdings, Inc.